Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BTMD NASDAQ:MCRB NASDAQ:RNXT NASDAQ:VTYX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBTMDbiote$3.45+2.4%$3.63$2.76▼$6.98$170.57M1.19172,018 shs129,569 shsMCRBSeres Therapeutics$15.69-1.4%$15.82$6.53▼$24.67$137.37M0.15115,816 shs151,689 shsRNXTRenovoRx$1.27-0.8%$1.16$0.75▼$1.69$46.55M1.24205,521 shs1.14 million shsVTYXVentyx Biosciences$2.30$2.68$0.78▼$3.39$164.01M0.951.29 million shs555,197 shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBTMDbiote0.00%-2.60%+15.41%-15.33%-42.49%MCRBSeres Therapeutics0.00%-17.82%-4.67%+112.13%-20.39%RNXTRenovoRx0.00%+3.23%+33.96%-2.29%+13.73%VTYXVentyx Biosciences0.00%-8.73%-18.73%-9.45%+0.44%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBTMDbiote$3.45+2.4%$3.63$2.76▼$6.98$170.57M1.19172,018 shs129,569 shsMCRBSeres Therapeutics$15.69-1.4%$15.82$6.53▼$24.67$137.37M0.15115,816 shs151,689 shsRNXTRenovoRx$1.27-0.8%$1.16$0.75▼$1.69$46.55M1.24205,521 shs1.14 million shsVTYXVentyx Biosciences$2.30$2.68$0.78▼$3.39$164.01M0.951.29 million shs555,197 shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBTMDbiote0.00%-2.60%+15.41%-15.33%-42.49%MCRBSeres Therapeutics0.00%-17.82%-4.67%+112.13%-20.39%RNXTRenovoRx0.00%+3.23%+33.96%-2.29%+13.73%VTYXVentyx Biosciences0.00%-8.73%-18.73%-9.45%+0.44%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBTMDbiote 2.50Moderate Buy$6.0073.91% UpsideMCRBSeres Therapeutics 1.75Reduce$73.67369.51% UpsideRNXTRenovoRx 3.00Buy$7.50490.55% UpsideVTYXVentyx Biosciences 2.50Moderate Buy$7.50226.09% UpsideCurrent Analyst Ratings BreakdownLatest RNXT, VTYX, BTMD, and MCRB Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/25/2025RNXTRenovoRxAscendiant Capital MarketsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$11.50 ➝ $12.008/7/2025BTMDbioteB. RileySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Neutral$8.00 ➝ $4.00(Data available from 9/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBTMDbiote$197.19M0.86$0.78 per share4.40($2.78) per share-1.24MCRBSeres TherapeuticsN/AN/AN/AN/A$1.61 per shareN/ARNXTRenovoRx$40K1,163.64N/AN/A$0.19 per share6.68VTYXVentyx BiosciencesN/AN/AN/AN/A$3.59 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBTMDbiote$3.16M$0.903.836.39N/A15.73%-21.00%18.26%11/11/2025 (Estimated)MCRBSeres Therapeutics$140K-$4.60N/AN/AN/AN/A-350.16%-67.69%11/12/2025 (Estimated)RNXTRenovoRx-$8.81M-$0.38N/AN/AN/AN/A-120.68%-89.23%11/12/2025 (Estimated)VTYXVentyx Biosciences-$135.12M-$1.68N/AN/AN/AN/A-48.89%-44.87%11/6/2025 (Estimated)Latest RNXT, VTYX, BTMD, and MCRB EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025RNXTRenovoRx-$0.08-$0.08N/A-$0.08$0.25 million$0.42 million8/7/2025Q2 2025VTYXVentyx Biosciences-$0.45-$0.38+$0.07-$0.38N/AN/A8/6/2025Q2 2025BTMDbiote$0.06$0.10+$0.04$0.10$49.52 million$48.86 million8/6/2025Q2 2025MCRBSeres Therapeutics-$2.72-$2.27+$0.45-$2.27$11.75 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBTMDbioteN/AN/AN/AN/AN/AMCRBSeres TherapeuticsN/AN/AN/AN/AN/ARNXTRenovoRxN/AN/AN/AN/AN/AVTYXVentyx BiosciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBTMDbioteN/A0.980.74MCRBSeres TherapeuticsN/A1.571.57RNXTRenovoRxN/A8.618.61VTYXVentyx BiosciencesN/A19.1219.12Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBTMDbiote21.68%MCRBSeres Therapeutics59.34%RNXTRenovoRx3.10%VTYXVentyx Biosciences97.88%Insider OwnershipCompanyInsider OwnershipBTMDbiote24.00%MCRBSeres Therapeutics4.70%RNXTRenovoRx9.13%VTYXVentyx Biosciences18.18%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBTMDbiote19449.44 million37.57 millionNot OptionableMCRBSeres Therapeutics3308.76 million8.34 millionOptionableRNXTRenovoRx636.65 million33.30 millionNot OptionableVTYXVentyx Biosciences3071.31 million58.35 millionOptionableRNXT, VTYX, BTMD, and MCRB HeadlinesRecent News About These CompaniesIeq Capital LLC Takes Position in Ventyx Biosciences, Inc. $VTYXSeptember 9, 2025 | marketbeat.comNuveen LLC Makes New $194,000 Investment in Ventyx Biosciences, Inc. $VTYXSeptember 8, 2025 | marketbeat.comADAR1 Capital Management LLC Purchases 157,070 Shares of Ventyx Biosciences, Inc. $VTYXSeptember 4, 2025 | marketbeat.comRedmile Group LLC Raises Holdings in Ventyx Biosciences, Inc. $VTYXSeptember 4, 2025 | marketbeat.comVentyx Biosciences to Participate in Three Upcoming Investor ConferencesAugust 27, 2025 | globenewswire.comH.C. Wainwright Keeps Their Hold Rating on Ventyx Biosciences (VTYX)August 23, 2025 | theglobeandmail.comPiper Sandler Reaffirms Their Buy Rating on Ventyx Biosciences (VTYX)August 23, 2025 | theglobeandmail.comVentyx Biosciences Reports Decreased Losses in 2025August 15, 2025 | msn.com3 Best Stocks to Buy Now, 8/11/2025, According to Top AnalystsAugust 11, 2025 | msn.comVentyx Biosciences Reports Second Quarter 2025 Financial Results and Highlights Recent Corporate ProgressAugust 9, 2025 | finance.yahoo.comVentyx (VTYX) Q2 Net Loss Drops 16%August 9, 2025 | theglobeandmail.comIs Ventyx Biosciences (NASDAQ:VTYX) In A Good Position To Invest In Growth?July 22, 2025 | uk.finance.yahoo.comVentyx Biosciences (VTYX) Upgraded to Strong Buy: What Does It ... - NasdaqJuly 11, 2025 | nasdaq.comVentyx Biosciences (VTYX) Upgraded to Strong Buy: What Does It Mean for the Stock?July 10, 2025 | zacks.comAnalysts Are Bullish on Top Healthcare Stocks: Eli Lilly & Co (LLY), Ventyx Biosciences (VTYX)June 24, 2025 | theglobeandmail.comVTYX - Ventyx Biosciences Inc News - MorningstarJune 24, 2025 | morningstar.comMVTYX - Ventyx Biosciences Inc Financials - MorningstarJune 24, 2025 | morningstar.comMVentyx Biosciences Insiders Placed Bullish Bets Worth US$1.26mJune 17, 2025 | finance.yahoo.comVentyx Biosciences' Study of VTX3232 Met Safety, Tolerability ObjectivesJune 17, 2025 | marketwatch.comVentyx says Parkinson’s disease drug hit main goal in small mid-stage trialJune 17, 2025 | msn.comVentyx Biosciences Holds Steady Despite Encouraging Early Parkinson’s Trial ResultsJune 17, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeRNXT, VTYX, BTMD, and MCRB Company Descriptionsbiote NASDAQ:BTMD$3.45 +0.08 (+2.37%) Closing price 04:00 PM EasternExtended Trading$3.44 -0.01 (-0.14%) As of 06:14 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.biote Corp. operates in practice-building business within the hormone optimization space. It trains physicians and nurse practitioners in hormone optimization using bioidentical hormone replacement pellet therapy in men and women experiencing hormonal imbalance. The company offers Biote Method, a comprehensive end-to-end practice building platform that provides Biote-certified practitioners with the components developed for practitioners in the hormone optimization space comprising Biote Method education, training, and certification services; practice management software that allows Biote-certified practitioners to order, track, and manage hormone optimization product inventory and other administrative requirements; inventory management software to monitor pellet inventory; and information regarding available hormone replacement therapy products, as well as digital and point-of-care marketing support. It also sells dietary supplements under the Biote brand; and sterile pellet insertion kits that is used with hormone optimization therapies for male and female. The company was founded in 2012 and is headquartered in Irving, Texas.Seres Therapeutics NASDAQ:MCRB$15.69 -0.22 (-1.38%) Closing price 04:00 PM EasternExtended Trading$15.54 -0.15 (-0.96%) As of 05:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Seres Therapeutics, Inc., a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state. The company's lead product candidate is VOWST, an oral microbiome therapeutic that has completed Phase III clinical trial for the treatment of recurrent Clostridioides difficile infection. Its product pipeline also includes SER-155, an investigational oral fermented microbiome therapeutic which is in Phase 1b clinical trials for the treatment of gastrointestinal infections, bacteremia, and graft versus host disease in immunocompromised patients including patients receiving allogeneic hematopoietic stem cell transplantation. In addition, the company engages in the development of SER-287 which is in Phase 2b and SER-301 that is in Phase 1b to treat ulcerative colitis. Further, it has license Agreement with NHSc Rx License GmbH for the therapeutic products based on the microbiome technology, which includes VOWST product candidate, which is developed for the treatment of CDI and recurrent CDI; and collaboration license agreement with Société des Produits Nestlé S.A. (Nestlé) for the development and commercialization of certain product candidates for the treatment and management of CDI and inflammatory bowel disease including UC and Crohn's disease. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015. Seres Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.RenovoRx NASDAQ:RNXT$1.27 -0.01 (-0.78%) Closing price 04:00 PM EasternExtended Trading$1.27 +0.00 (+0.39%) As of 06:29 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.RenovoRx, Inc., a clinical-stage biopharmaceutical company, focuses on developing proprietary targeted combination therapies to improve therapeutic outcomes for cancer patients undergoing treatment. Its lead product candidate is RenovoGem, an oncology drug-device combination product, consisting of intra-arterial gemcitabine and RenovoCath that is in Phase III clinical trials for the locally advanced pancreatic cancer. The company has a research collaboration with Imugene Limited to deliver oncolytic virus therapy for the treatment of difficult-to-access tumors. RenovoRx, Inc. was founded in 2009 and is headquartered in Los Altos, California.Ventyx Biosciences NASDAQ:VTYX$2.30 0.00 (0.00%) Closing price 04:00 PM EasternExtended Trading$2.33 +0.03 (+1.09%) As of 06:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company's lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn's disease. It is also developing VTX002, a sphingosine 1 phosphate receptor modulator that is in Phase II clinical trials for the treatment of ulcerative colitis; and VTX2735, a peripheral-targeted NOD-like receptor protein 3 inflammasome inhibitor to treat patients with cryopyrin-associated periodic syndrome. In addition, the company develops VTX3232, a CNS-penetrant NLRP3 inhibitor. Ventyx Biosciences, Inc. was incorporated in 2018 and is based in San Diego, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Palantir’s Commercial Growth Story Is Just Getting Started The Applied Digital Breakout Is Only the Beginning $100 Million Buyback in Upwork Stock Follows a Strong Quarter Royal Caribbean's 33% Dividend Hike Signals Deeper Growth MarketBeat Week in Review – 09/08 - 09/12 Adobe’s Rebound Has Room to Run: 25% Upside by Year-End Wall Street Eyes +30% Upside in Synopsys After Huge Earnings Fall Meta's $600B U.S. Investment: Bearish or Bullish for Shares? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
